A practical reference on MC1R: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-08 and is reviewed periodically as new material appears.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Cyclic heptapeptide, C-terminally amidated |
| Approximate molecular mass | 1024 Da | Monoisotopic mass of the free peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Soluble in water and polar solvents | Also dissolves in neutral aqueous buffer |
| Common synonyms | Melanotan II, MT-II, MT-2 | Described as a melanocortin agonist in early literature |
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
The vaginal flora is a complex ecosystem that changes throughout life, from birth to menopause. The vaginal microbiota resides in and on the outermost layer of the vaginal epithelium. This microbiome consists of species and genera, which typically do not cause symptoms or infections in women with normal immunity. The vaginal microbiome is dominated by Lactobacillus species. These species metabolize glycogen, breaking it down into sugar. Lactobacilli metabolize the sugar into glucose and lactic acid. Under the influence of hormones, such as estrogen, progesterone and follicle-stimulating hormone (FSH), the vaginal ecosystem undergoes cyclic or periodic changes.
=== Other appearances === Culp appeared in the 1993 live action video game Voyeur as the game's villain, industrialist/politician Reed Hawke. He lent his voice to the digital character Dr. Wallace Breen, the prime antagonist in the 2004 computer game Half-Life 2. The video clip of "Guilty Conscience" features Culp as an erudite and detached narrator describing the scenes where Eminem and Dr. Dre rap lyrics against each other. He only appears in the music video. In the album version, the narrator is Mark Avery. On November 9, 2007, on The O'Reilly Factor, host Bill O'Reilly interviewed Culp about the actor's career and awarded Culp with the distinction "TV Icon of the Week".
=== Hepatotoxicity === In large clinical trials, imipenem was associated with transient and asymptomatic elevations in serum aminotransferase levels in about 6% of patients given the drug for five to 14 days. More serious hepatic injury from imipenem/cilastatin is rare, but jaundice and liver test abnormalities have been reported in 0.1% of patients in prospective trials of the agent. Several instances of cholestatic jaundice arising during or shortly after therapy have been reported with imipenem-cilastatin and other carbapenems. The latency to onset has been within one to three weeks, and the pattern of enzyme elevations is usually cholestatic. Immunoallergic features can occur, but autoantibodies are rare. The course is usually self-limiting, but at least one case of vanishing bile duct syndrome related to the carbapenems has been reported. Imipenem and other carbapenems have not been linked to cases of acute liver failure.
==== Two-state substitution models ==== An alternative way to analyze DNA sequence data is to recode the nucleotides as purines (R) and pyrimidines (Y); this practice is often called RY-coding. Insertions and deletions in multiple sequence alignments can also be encoded as binary data and analyzed in using a two-state model. The simplest two-state model of sequence evolution is called the Cavender-Farris model or the Cavender-Farris-Neyman (CFN) model; the name of this model reflects the fact that it was described independently in several different publications. The CFN model is identical to the Jukes-Cantor model adapted to two states and it has been implemented as the "JC2" model in the popular IQ-TREE software package (using this model in IQ-TREE requires coding the data as 0 and 1 rather than R and Y; the popular PAUP* software package can interpret a data matrix comprising only R and Y as data to be analyzed using the CFN model). It is also straightforward to analyze binary data using the phylogenetic Hadamard transform. The alternative two-state model allows the equilibrium frequency parameters of R and Y (or 0 and 1) to take on values other than 0.5 by adding a single free parameter; this model is variously called CFu or GTR2 (in IQ-TREE). This issue is not too commonly encountered in nucleotide sequences, but can matter a lot for other types of binary data such as the presence or absence of a morphological innovation.
==== Bands ==== Opus (Austrian band), an Austrian pop-rock group Opus (Yugoslav band), a Yugoslav progressive rock group Opus (Latvian band), Latvian music group Pur (band), a German pop group originally known as "Opus"
Sources: en.wikipedia.org
Corticotropic releasing hormone (CRH): stimulates ACTH secretion Thyrotropin releasing hormone (TRH): stimulates TSH and prolactin secretion Growth hormone releasing hormone (GHRH): stimulates GH secretion Somatostatin: inhibits GH (and other hormone) secretion Gonadotropin releasing hormone (GnRH): stimulates FSH and LH secretion Prolactin releasing hormone (PRH): stimulates PRL secretion Prolactin inhibiting hormone (dopamine): inhibits PRL secretion These hypothalamic hormones are secreted in pulses. They act on specific membrane receptors. They are also glycoproteins. They stimulate:
The legality of drug prohibition within the US has been challenged on various grounds. One argument holds that drug prohibition, as presently implemented, violates the substantive due process doctrine in that its benefits do not justify the encroachments on rights that are supposed to be guaranteed by the Fifth and Fourteenth Amendments to the US Constitution. Another argument interprets the Commerce Clause to mean that drugs should be regulated in state law not federal law. A third argument states that the reverse burden of proof in drug-possession cases is incompatible with the rule of law, in that the power to convict is effectively taken from the courts and given to those who are willing to plant evidence.
One mode of monazite formation is crystallization from an igneous melt. The concentric zoning pattern reflects the changing composition of the melt which affects the composition of the crystallizing monazite.
We also can now have high confidence in the judgment that there were no successful "moles" at the political decision-making level on either side. Similarly, there is no evidence, on either side, of any major political or military decision that was prematurely discovered through espionage and thwarted by the other side. There also is no evidence of any major political or military decision that was crucially influenced (much less generated) by an agent of the other side. According to historian Robert L. Benson, "Washington's forte was 'signals' intelligence – the procurement and analysis of coded foreign messages," leading to the Venona project or Venona intercepts, which monitored the communications of Soviet intelligence agents. Moynihan wrote that the Venona project contained "overwhelming proof of the activities of Soviet spy networks in America, complete with names, dates, places, and deeds." The Venona project was kept highly secret even from policymakers until the Moynihan Commission in 1995. Despite this, the decryption project had already been betrayed and dispatched to the USSR by Kim Philby and Bill Weisband in 1946, as was discovered by the US by 1950. Nonetheless, the Soviets had to keep their discovery of the program secret, too, and continued leaking their own information, some of which was still useful to the American program. According to Moynihan, even President Truman may not have been fully informed of Venona, which may have left him unaware of the extent of Soviet espionage.
Sources: en.wikipedia.org
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.
Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.
Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.